secwatch.observer — SEC 8-K summary
======================================

Issuer:     Climb Bio, Inc. (CLYM)
CIK:        0001768446
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001193125-26-210295
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Climb Bio reports Q1 2026 cash of $146.3M; $110M private placement closed April 29
--------------------------------------------------------------------------------

- R&D expense $9.4M vs $17.3M YoY (incl. $9M CLYM116 upfront in prior year); G&A $5.8M.
- Cash, equivalents, and marketable securities $146.3M as of March 31; expects to fund ops into 2028 excluding $110M placement.
- Budoprutug SC formulation showed robust B-cell depletion similar to IV; Phase 2 pMN trial granted FDA Fast Track Designation.
- Initial budoprutug ITP data (low-dose B-cell and platelet) expected June 2026; pMN data Q4 2026.
- CLYM116 nonhuman primate-to-human PK/PD modeling and initial safety data to be presented at ERA June 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768446/000119312526210295/0001193125-26-210295-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768446/000119312526210295/clym-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-210295

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer